Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

960

Participants

Timeline

Start Date

December 1, 2022

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions
HIVOrgan TransplantationLymphoma, Non-HodgkinChronic Lymphocytic LeukemiaMultiple MyelomaCOVID-19 Vaccines
Interventions
BIOLOGICAL

Pfizer Bivalent COVID-19 Vaccine

One or Two doses three months apart, per manufacturer's recommendations.

BIOLOGICAL

Moderna Bivalent mRNA vaccine

One or Two doses three months apart, per manufacturer's recommendations.

Trial Locations (13)

2031

Prince Of Wales Hospital, Randwick

2145

Westmead Hospital, Westmead

3000

Peter MacCallum Cancer Centre, Melbourne

Royal Melbourne Hospital, Melbourne

3004

Alfred Health, Melbourne

3065

St Vincents Hospital, Fitzroy

3084

Austin Hospital, Heidelberg

3168

Monash Medical Centre, Clayton

3220

University Geelong Hospital, Geelong

4029

Royal Brisbane and Womens Hospital, Herston

4102

Princess Alexandra Hospital, Woolloongabba

5000

Royal Adelaide Hospital, Adelaide

Unknown

St Vincents Hospital, Darlinghurst

All Listed Sponsors
collaborator

The University of Sydney, Sydney, Australia

UNKNOWN

collaborator

University of Melbourne

OTHER

lead

Monash University

OTHER